As the IAS Conference on HIV Science kicks off in Mexico City, we explain how an investigational HIV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson works—and how researchers hope to help change lives around the world with it.
The condition affects 36 million people around the world, yet it can be surprisingly difficult to recognize—for both patients and healthcare professionals. Learn why Johnson & Johnson continues to advance approaches for this often-misunderstood mental health disorder.
Cardiovascular disease is the leading cause of death around the world. For Roberta Chapman, Alistair Lindsay and JoAnne Foody the pursuit of better treatments is both a professional mission and a deeply personal one.
Scientists are better understanding the neuropsychiatric changes that strike up to 97% of patients diagnosed with this degenerative brain disease. Here’s what to know about these often distressing symptoms, and why Johnson & Johnson is working on a solution.